J-GLOBAL         Last updated: Oct 25, 2019 at 14:17
Tohoku University
New Industry Creation Hatchery Center
Job title


Dr. Nonogaki has worked as a Postdoc Research Fellow at the University of California, San Francisco and the Scripps Research Institute, La Jolla. He has studied central serotonin network in the regulation of appetite and energy homeostasis. Lorcaserin (Belviq), a selective 5-HT2C receptor agonist, which is used for the treatment of obesity, is based on the original research works by Dr. Nonogaki et al. Current studies are to determine the network of gut-derived hormones and liver-derived hormones in the regulation of obesity and type 2 diabetes. Dr. Nonogaki also has a novel ultrasound irradiation device for hypertension and diabetes.

Research Areas


Published Papers

Nonogaki K, Murakami M, Yamazaki T, Nonogaki N
International journal of cardiology. Heart & vasculature   19 34-36   Jun 2018   [Refereed]
A Tryptophan Hydroxylase Inhibitor Increases Hepatic FGF21 Production and Decreases Hepatic Gluconeogenesis Independently of Insulin in db/db Mice
Nonogaki K, Kaji T, Murakami M
Neuropsychiatry   8(4) 1476-1481   2018   [Refereed]
A Tryptophan Hydroxylase Inhibitor Decreases Hepatic FGF21 Expression and Circulating FGF21 in Mice Fed A High-Fat Diet
Nonogaki K, Kaji T, Murakami M
Neuropsychiatry   8(1) 372-377   2018   [Refereed]
Nonogaki K, Murakami M, Yamazaki T, Nonogaki N
International journal of cardiology. Heart & vasculature   16 4-6   Sep 2017   [Refereed]
Nonogaki K, Kaji T
Neuroscience letters   638 35-38   Jan 2017   [Refereed]
Nonogaki K, Yamazaki T, Murakami M, Satoh N, Hazama M, Takeda K, Tsujita N, Katoh S, Kubota N
International journal of cardiology   215 147-149   Jul 2016   [Refereed]
Nonogaki K, Kaji T, Yamazaki T, Murakami M
Neuroscience letters   612 14-17   Jan 2016   [Refereed]
Decreased energy intake versus increased lipolysis in the prevention of type 2 diabetes.
Nonogaki K
Integr Obesity Diabetes.   2(5) 1-1   2016   [Refereed]